The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2005
DOI: 10.1001/jama.294.16.2043
|View full text |Cite
|
Sign up to set email alerts
|

Changing Epidemiology of Invasive Pneumococcal Disease Among Older Adults in the Era of Pediatric Pneumococcal Conjugate Vaccine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

22
381
1
20

Year Published

2007
2007
2017
2017

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 618 publications
(424 citation statements)
references
References 25 publications
(22 reference statements)
22
381
1
20
Order By: Relevance
“…An important event during the study period is the implementation of infant vaccination against IPD (PCV7) through the Dutch national immunization program in 2006. In the United States, a decline in IPD cases was detected post‐vaccination in the non‐vaccinated elderly, referred to as indirect immunity 44. A study comparing cumulative IPD incidences over the pre‐vaccination years 2004‐2006 and late post‐vaccination period 2008‐2010 suggested a decline in IPD incidence in infants (age<2 years) and elderly (>65 years) 45.…”
Section: Discussionmentioning
confidence: 99%
“…An important event during the study period is the implementation of infant vaccination against IPD (PCV7) through the Dutch national immunization program in 2006. In the United States, a decline in IPD cases was detected post‐vaccination in the non‐vaccinated elderly, referred to as indirect immunity 44. A study comparing cumulative IPD incidences over the pre‐vaccination years 2004‐2006 and late post‐vaccination period 2008‐2010 suggested a decline in IPD incidence in infants (age<2 years) and elderly (>65 years) 45.…”
Section: Discussionmentioning
confidence: 99%
“…For PCV7 and other PCV13, the safety efficacy and effectiveness have been, in practice, established in different settings [22,23]. 13-valent pneumococcal conjugate vaccine includes capsular antigens of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F [24]. The implementation of the 13-valent pneumococcal conjugate vaccine for children under 2-year-old in Argentina could be an effective strategy to be implemented in other countries for the decrease in invasive disease [25] and nasopharyngeal carriage of S. pneumonia [26].…”
Section: Discussionmentioning
confidence: 99%
“…24 However, the nationwide implementation of vaccine recommendations also significantly decreased the incidence of IPD among U.S. adults aged ≥65 years. 25 Streptococcus pneumoniae infections by serotypes in PCV13 in adults aged ≥65 years declined approximately 50% beginning in 2010 (when PCV13 replaced PCV7 in the routine childhood immunization schedule). Not taking the community protection into account when making recommendations can underestimate the benefits of vaccinating the group for whom vaccine is recommended, causing underestimation of the economic and health benefits.…”
Section: Community Protectionmentioning
confidence: 99%